[THE INVESTOR] On Oct. 10, Daewoong Pharma (069620) fell 4.22% to 26,100 won (US$23.45). It had declined 0.26% through the past month. Standard deviation, which indicates risk, records 2.7% on the same period over one month.

Compared with its close competitors within the same industry, KOSPI, evne though the investment return of Daewoong Pharma was the most satisfactory among its peer group, its volatility for 1 month was considerably higher than that of its peer group's. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was 0.1%. Though the volatility was high, the return-on-risk recorded the highest among its peer group as a satisfactory stock price. Moreover, compared with the KOSPI industry, the return-on-risk is much better than the industrial mean, -0.5, and thus the industrial comparison performance was good.

As of Oct. 9, institutions have been selling for the past 5 trading days and foreigners have been selling for the past 3 trading days. As a shareholding sum by investor group for the past 4 weeks, institutions have bought 74,356 shares in spite of lowered the position recently. However, during the same period, foreigners have sold 37,219 shares with maintenance of a selling position and Individuals have sold 37,137 shares in a lessening selling trend.

Cumulated shareholdings per investor group (1Mo) Total shareholdings per investor group

By HeRo (hero@heraldcorp.com)

This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.